Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
Standard
Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. / Wyen, Christoph; Jensen, Björn; Hentrich, Marcus; Siehl, Jan; Sabranski, Michael; Esser, Stefan; Gillor, Daniel; Müller, Markus; van Lunzen, Jan; Wolf, Timo; Bogner, Johannes R; Wasmuth, Jan C; Christ, Hildegard; Fätkenheuer, Gerd; Hoffmann, Christian.
in: AIDS, Jahrgang 26, Nr. 4, 4, 2012, S. 457-464.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of AIDS-related lymphomas: rituximab is beneficial even in severely immunosuppressed patients.
AU - Wyen, Christoph
AU - Jensen, Björn
AU - Hentrich, Marcus
AU - Siehl, Jan
AU - Sabranski, Michael
AU - Esser, Stefan
AU - Gillor, Daniel
AU - Müller, Markus
AU - van Lunzen, Jan
AU - Wolf, Timo
AU - Bogner, Johannes R
AU - Wasmuth, Jan C
AU - Christ, Hildegard
AU - Fätkenheuer, Gerd
AU - Hoffmann, Christian
PY - 2012
Y1 - 2012
N2 - AIDS-related lymphomas (ARLs) significantly contribute to mortality in HIV-infected patients. Optimal chemotherapy treatment and the use of rituximab remain controversial. The aim of the present cohort study was to analyze the outcome of HIV-infected patients diagnosed with ARL, with regard to the use of rituximab, clinical characteristics and histopathological markers.
AB - AIDS-related lymphomas (ARLs) significantly contribute to mortality in HIV-infected patients. Optimal chemotherapy treatment and the use of rituximab remain controversial. The aim of the present cohort study was to analyze the outcome of HIV-infected patients diagnosed with ARL, with regard to the use of rituximab, clinical characteristics and histopathological markers.
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Cohort Studies
KW - Prognosis
KW - Follow-Up Studies
KW - Disease-Free Survival
KW - Antiretroviral Therapy, Highly Active
KW - CD4 Lymphocyte Count
KW - Drug Therapy, Combination
KW - Germany/epidemiology
KW - Tumor Markers, Biological/metabolism
KW - Antineoplastic Agents/pharmacology/therapeutic use
KW - Acquired Immunodeficiency Syndrome/drug therapy/immunology/mortality
KW - Antibodies, Monoclonal, Murine-Derived/pharmacology/therapeutic use
KW - Antigens, CD20/drug effects/metabolism
KW - CD4-Positive T-Lymphocytes/drug effects/metabolism
KW - Immunocompromised Host
KW - Lymphoma, AIDS-Related/drug therapy/immunology/mortality
KW - Adult
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Young Adult
KW - Cohort Studies
KW - Prognosis
KW - Follow-Up Studies
KW - Disease-Free Survival
KW - Antiretroviral Therapy, Highly Active
KW - CD4 Lymphocyte Count
KW - Drug Therapy, Combination
KW - Germany/epidemiology
KW - Tumor Markers, Biological/metabolism
KW - Antineoplastic Agents/pharmacology/therapeutic use
KW - Acquired Immunodeficiency Syndrome/drug therapy/immunology/mortality
KW - Antibodies, Monoclonal, Murine-Derived/pharmacology/therapeutic use
KW - Antigens, CD20/drug effects/metabolism
KW - CD4-Positive T-Lymphocytes/drug effects/metabolism
KW - Immunocompromised Host
KW - Lymphoma, AIDS-Related/drug therapy/immunology/mortality
M3 - SCORING: Journal article
VL - 26
SP - 457
EP - 464
JO - AIDS
JF - AIDS
SN - 0269-9370
IS - 4
M1 - 4
ER -